

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 49/02, 43/00	A1	(11) International Publication Number: WO 93/17719 (43) International Publication Date: 16 September 1993 (16.09.93)
(21) International Application Number: PCT/US93/02320 (22) International Filing Date: 12 March 1993 (12.03.93) (30) Priority data: 851,074 13 March 1992 (13.03.92) US (60) Parent Application or Grant (63) Related by Continuation US 851,074 (CIP) Filed on 13 March 1992 (13.03.92) (71) Applicant (for all designated States except US): DIATECH, INC. [US/US]; 9 Delta Drive, Londonderry, NH 03053 (US).		(72) Inventors; and (75) Inventors/Applicants (for US only) : DEAN, Richard, T. [US/US]; 43 King Road, Bedford, NH 03110 (US). LEES, Robert, S. [US/US]; 203 Clinton Road, Brookline, MA 02146 (US). BUTTRAM, Scott [US/US]; 12 Gervaise Drive, Derry, NH 03038 (US). LISTER-JAMES, John [GB/US]; 25 Old Stone Way, Bedford, NH 03110 (US). (74) Agent: NOONAN, Kevin, E.; Allegretti & Witcoff, Ltd., Ten South Wacker Drive, Chicago, IL 60606 (US). (81) Designated States: AU, CA, JP, KR, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: TECHNETIUM-99m LABELED PEPTIDES FOR IMAGING INFLAMMATION (57) Abstract This invention relates to radiolabeled peptides and methods for producing such peptides. Specifically, the invention relates to technetium-99m (Tc-99m) labeled leukocyte-binding peptides, methods and kits for making such peptides, and methods for using such peptides to image sites of infection and inflammation in a mammalian body.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

TECHNETIUM-99m LABELED PEPTIDES FOR IMAGING INFLAMMATION

BACKGROUND OF THE INVENTION

5

1. Field of the Invention

This invention relates to radiodiagnostic agents and reagents for preparing such agents, and also methods for producing radiolabeled radiodiagnostic agents. Specifically, the invention relates to technetium-99m (Tc-99m) labeled agents, methods and kits for making such agents, and methods for using such agents to image sites of infection and inflammation in a mammalian body.

10

2. Description of the Prior Art

15

A variety of radionuclides are known to be useful for radioimaging, including ^{67}Ga , $^{99\text{m}}\text{Tc}$ (Tc-99m), ^{111}In , ^{123}I , ^{125}I , ^{169}Yb or ^{186}Re . The sensitivity of imaging methods using radioactively-labeled peptides is much higher than other techniques known in the art, since the specific binding of the radioactive peptide concentrates the radioactive signal over the area of interest, for example, an inflammatory site.

20

There is a clinical need to be able to determine the location and/or extent of sites of focal or localized infection. In a substantial number of cases conventional methods of diagnosis (such as physical examination, x-ray, CT and ultrasonography) fail to identify such sites (*e.g.*, an abscess). In some cases, biopsy may be resorted to, but is preferably avoided at least until it is necessary in order to identify the pathogen responsible for an abscess at a known location. Identifying the site of such "occult" infection is important because rapid localization of the problem is critical to effective therapeutic intervention.

25

30

In the field of nuclear medicine, certain pathological conditions can be localized or the extent of such conditions determined by imaging the internal distribution of administered radioactively-labeled tracer compounds (*i.e.* radiotracers or radiopharmaceuticals) that accumulate specifically at the

pathological site. However, an abscess may be caused by any one of many possible pathogens, so that a radiotracer specific for a particular pathogen would have limited scope. On the other hand, infection is almost invariably accompanied by inflammation, which is a general response of the body to tissue injury. Therefore, a radiotracer specific for sites of inflammation would be expected to be useful in localizing sites of infection caused by any pathogen.

One of the main phenomena associated with inflammation is the localization of leukocytes (white blood cells), usually monocytes and neutrophils, at the site of inflammation. A radiotracer specific for leukocytes would be useful in detecting leukocytes at the site of a localized infection. Currently approved nuclear medicine procedures for imaging sites of infection use either indium-111 labeled leukocytes (^{111}In -WBC) (*see, e.g.* Peters, 1992, J. Nucl. Med. 33: 65-67) or gallium-67 (^{67}Ga) citrate (*see, e.g.* Ebright *et al.*, 1982, Arch. Int. Med. 142: 246-254).

A major disadvantage of using ^{111}In -labeled WBCs is that the preparation of the radiotracer requires sterile removal of autologous blood, sterile isolation of the leukocytes from the blood, sterile labeling of the leukocytes using conditions that do not damage the cells (since damaged WBC are taken up by the reticuloendothelial system when re-injected) and return (re-injection) of the (now labeled) leukocytes to the patient. Furthermore, a delay of 12 to 48 hours between injection and imaging may be required for optimal images. While Tc-99m labeled leukocytes have been used to shorten this delay period (*see, e.g.* Vorne *et al.*, 1989, J. Nucl. Med. 30: 1332-1336), ex-corporeal labeling is still required. A preferred radiotracer would be one that does not require removal and manipulation of autologous blood components.

^{67}Ga -citrate can be administered by intravenous injection. However, this compound is not specific for sites of infection or inflammation. Moreover, a delay of up to 72 hours is often required between injection of the radiotracer and imaging. In addition, the γ -(gamma) emission energies of ^{67}Ga are not well suited to conventional gamma cameras.

Radiolabeled monoclonal and polyclonal antibodies raised against human leukocytes (including monocytes, neutrophils, granulocytes and other) have been developed. Tc-99m labeled antigranulocyte monoclonal antibodies (*see, e.g. Lind et al.*, 1990, J. Nucl. Med. 31: 417-473) and ¹¹¹In-labeled non-specific human immunoglobulin (*see, e.g. LaMuraglia et al.*, 1989, J. Vasc. Surg. 10: 20-28) have been tested for the detection of inflammation secondary to infection. ¹¹¹In-labeled IgG shares the disadvantages of ¹¹¹In-labeled WBC, in that 24-48 hours are required between injection and optimal imaging. In addition, all radiolabeled antibodies are difficult to produce and face protracted regulatory agency approval procedures as biologics.

Small readily synthesized molecules are preferred for routinely used radiopharmaceuticals. There is clearly a need for small synthetic molecules that can be directly injected into a patient and will image sites of infection and inflammation by localizing at sites where leukocytes have accumulated.

One class of compounds known to bind to leukocytes are chemotactic peptides that cause leukocytes to move up a peptide concentration gradient (*see Wilkinson*, 1988, Meth. Enzymol. 162: 127-132). These compounds bind to receptors on the surface of leukocytes with very high affinity. These peptides are derived from a number of sources, including complement factors, bacteria, tuftsin, elastin, fibrinopeptide B, fibrinogen B β , platelet factor 4 and others. Small synthetic peptides derived from these chemotactic compounds and radiolabeled would be very useful as radiotracers for imaging sites of inflammation *in vivo*.

Radiolabeled peptides have been reported in the prior art.

U.S. Patent No. 4,986,979 relates to the use of radiolabeled chemotactic formyl peptides to radiolabel leukocytes ex-corporeally *via* a photoaffinity label.

EPC 90108734.6 relates to chemotactic formyl peptide - ¹¹¹In-labeled DTPA conjugates.

PCT W090/10463 relates to the use of radiolabeled chemotactic formyl peptides to radiolabel leukocytes ex-corporeally *via* a photoaffinity label.

Zoghbi *et al.*, 1981, J. Nucl. Med. 22: 32 (Abst) disclose formyl

peptide chemotactic factors derived from bacteria coupled to ^{111}In -labeled transferrin.

Jiang *et al.*, 1982, Nuklearmedizin 21: 110-113 disclose a chemotactic formylated peptide radiolabeled with ^{125}I .

5 Fischman *et al.*, 1991, J. Nucl. Med. 32: 482-491 relates to chemotactic formyl peptide - ^{111}In -labeled DTPA conjugates.

10 The use of chelating agents for radiolabeling polypeptides, methods for labeling peptides and polypeptides with Tc-99m are known in the prior art and are disclosed in co-pending U.S. Patent Applications Serial Nos. 07/653,012, 07/807,062, 07/871,282, and 07/893,981, which are hereby incorporated by reference.

SUMMARY OF THE INVENTION


The present invention provides scintigraphic imaging agents that are peptide reagents radioactively-labeled with Tc-99m. The peptide reagents of the invention are comprised of specific binding peptides that bind leukocytes, covalently linked to a Tc-99m radiolabel binding moiety.

A first aspect of the invention comprises reagents for preparing scintigraphic imaging agents for imaging sites of inflammation within a mammalian body, said reagents comprising a leukocyte binding peptide having an amino acid sequence comprising between 3 and 100 amino acids and a Tc-99m radiolabel-binding moiety.

In a second aspect, the invention comprises a Tc-99m radiolabel binding moiety which forms a Tc-99m complex having a net charge of [-1].

In yet another aspect, the radiolabeled peptide reagents of the invention comprise a specific binding peptide that binds to leukocytes, and a Tc-99m radiolabel-binding moiety of formula

I.



wherein Cp is a protected cysteine residue and (aa) stands for an amino acid, and wherein the radiolabel-binding moiety is covalently linked to the specific binding peptide. In a preferred embodiment, the amino acid is glycine. In another preferred embodiment, the radiolabel-binding moiety is linked to the specific peptide *via* one or more amino acids.

In another aspect, the invention provides peptide reagents comprising a Tc-99m radiolabel-binding moiety having the following structure:

II.




wherein A is H, HOOC, H₂NOC, (peptide)-NHOC, (peptide)-OOC or R⁴; B is H, SH or -NHR³, -N(R³)-(peptide) or R⁴; Z is H or R⁴; X is SH or -NHR³, -N(R³)-(peptide) or R⁴; R¹, R², R³ and R⁴ are independently H or straight or branched chain or cyclic lower alkyl; n is 0, 1 or 2; and: (1) where B is -NHR³ or -N(R³)-(peptide), X is SH and n is 1 or 2; (2) where X is -NHR³ or

-N(R³)-(peptide), B is SH and n is 1 or 2; (3) where B is H or R⁴, A is HOOC, H₂NOC, (peptide)-NHOC or (peptide)-OOC, X is SH and n is 0 or 1; (4) where A is H or R⁴, then where B is SH, X is -NHR³ or -N(R³)-(peptide) and where X is SH, B is -NHR³ or -N(R³)-(peptide); (5) where X is H or R⁴, A is HOOC, H₂NOC, (peptide)-NHOC or (peptide)-OOC and B is SH; (6) where Z is methyl, X is methyl, A is HOOC, H₂NOC, (peptide)-NHOC or (peptide)-OOC and B is SH and n is 0; and (7) where Z is SH and X is SH, n is not 0; and wherein the thiol moiety is in the reduced form.


Another aspect of the invention provides reagents for preparing scintigraphic imaging agents for imaging sites of inflammation within a mammalian body, the reagents comprising a leukocyte-binding peptide having an amino acid sequence comprising between 3 and 100 amino acids and a Tc-99m radiolabel-binding moiety that forms a Tc-99m complex that is electrochemically neutral.

In yet another aspect, the present invention provides reagents comprising leukocyte-binding peptides covalently linked to a Tc-99m radiolabel-binding moiety having the following structure:



[for purposes of this invention, radiolabel-binding moieties having this structure will be referred to as picolinic acid (Pic)-based moieties];

or




[for purposes of this invention, radiolabel-binding moieties having this structure will be referred to as picolylamine (Pica)-based moieties]; wherein X is H or a protecting group; (amino acid) is any amino acid; the Tc-99m radiolabel-binding moiety is covalently linked to the peptide, and the complex of the radiolabel-binding moiety and Tc-99m is electrically neutral. In a preferred

30

embodiment, the amino acid is glycine and X is an acetamidomethyl protecting group. In additional preferred embodiments, the peptide is covalently linked to the Tc-99m radiolabel-binding moiety *via* an amino acid, most preferably glycine.

5 In yet another embodiment of the invention, reagents are provided for preparing scintigraphic imaging agents for imaging sites within a mammalian body, comprising a specific binding peptide and a bisamino bisthiol Tc-99m radiolabel-binding moiety covalently linked to the peptide. The bisamino bisthiol Tc-99m radiolabel-binding moiety in this embodiment of the invention
10 has a formula selected from the group consisting of:


V.



15

wherein each R^5 can be independently H, CH_3 or C_2H_5 ; each $(\text{pgp})^s$ can be independently a thiol protecting group or H; m, n and p are independently 2 or 3; A is linear or cyclic lower alkyl, aryl, heterocyclyl, combinations or substituted derivatives thereof; and X is a peptide;

VI.



25

wherein each R^5 is independently H, lower alkyl having 1 to 6 carbon atoms, phenyl, or phenyl substituted with lower alkyl or lower alkoxy; m, n and p are independently 1 or 2; A is linear or cyclic lower alkyl, aryl, heterocyclyl, combinations or substituted derivatives thereof; V is H or CO-peptide; R^6 is H or a peptide; provided that when V is H, R^6 is a peptide and when R^6 is H, V is a peptide. [For purposes of this invention, radiolabel-binding moieties
30 having these structures will be referred to as "BAT" moieties]. In one

preferred embodiment, the peptide is covalently linked to the Tc-99m radiolabel-binding moiety *via* an amino acid, most preferably glycine.

The specific binding peptides of the invention may also be covalently linked to a polyvalent linking moiety. Polyvalent linking moieties of the invention are comprised of at least 2 identical linker functional groups capable of covalently bonding to specific binding peptides or Tc-99m binding moieties. Preferred linker functional groups are primary or secondary amines, hydroxyl groups, carboxylic acid groups or thiol-reactive groups. In preferred embodiments, the polyvalent linking moieties are comprised of *bis*-succinimidylmethylether (BSME), 4-(2,2-dimethylacetyl)benzoic acid (DMAB) and *tris*(succinimidylethyl)amine (TSEA).

The invention comprises scintigraphic imaging agents that are complexes between the reagents of the invention and Tc-99m, and methods for radiolabeling the reagents of the invention with Tc-99m. Radiolabeled complexes provided by the invention are formed by reacting the reagents of the invention with Tc-99m in the presence of a reducing agent. Preferred reducing agents include but are not limited to dithionite ion, stannous ion and ferrous ion. Complexes of the invention are also formed by labeling the reagents of the invention with Tc-99m by ligand exchange of a prereduced Tc-99m complex as provided herein.

The invention also provides kits for preparing scintigraphic imaging agents that are the reagents of the invention radiolabeled with Tc-99m. Kits for labeling the reagents provided by the invention with Tc-99m are comprised of a sealed vial containing a predetermined quantity of a reagent of the invention and a sufficient amount of reducing agent to label the reagent with Tc-99m.

This invention provides methods for preparing peptide reagents of the invention by chemical synthesis *in vitro*. In a preferred embodiment, peptides are synthesized by solid phase peptide synthesis.

This invention provides methods for using scintigraphic imaging agents that are Tc-99m labeled reagents for imaging sites of inflammation within a

5 mammalian body by obtaining *in vivo* gamma scintigraphic images. These methods comprise administering an effective diagnostic amount of Tc-99m labeled reagents of the invention and detecting the gamma radiation emitted by the Tc-99m label localized at the site of inflammation within the mammalian body.

Specific preferred embodiments of the present invention will become evident from the following more detailed description of certain preferred embodiments and the claims.

10 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 illustrates a gamma-scintiphoto of a New Zealand white rabbit treated as described in Example 3.

DETAILED DESCRIPTION OF THE INVENTION

15 The present invention provides reagents for preparing Tc-99m radiolabeled scintigraphic imaging agents for imaging target sites within a mammalian body. The reagents comprise a specific binding peptide that binds to leukocytes, covalently linked to a Tc-99m radiolabel complexing group.

20 The peptides of this invention bind to leukocytes, preferably monocytes and neutrophils and most preferably to neutrophils. For purposes of this invention, the term "bind to leukocytes" is intended to mean that the peptides of the present invention are capable of accumulating at sites of infection or inflammation in mammalian body sufficient to allow detection of such sites by gamma scintigraphy.

25 In Cp(aa)Cp-containing peptides, the Cp is a protected cysteine where the S-protecting groups are the same or different and may be but not limited to:

- CH₂-aryl (aryl is phenyl or alkyl or alkyloxy substituted phenyl);
- CH-(aryl)₂, (aryl is phenyl or alkyl or alkyloxy substituted phenyl);
- 30 -C-(aryl)₃, (aryl is phenyl or alkyl or alkyloxy substituted phenyl);
- CH₂-(4-methoxyphenyl);

- CH-(4-pyridyl)(phenyl)₂;
- C(CH₃)₃
- 9-phenylfluorenyl;
- CH₂NHCOR (R is unsubstituted or substituted alkyl or aryl);
- 5 -CH₂NHCOOR (R is unsubstituted or substituted alkyl or aryl);
- CONHR (R is unsubstituted or substituted alkyl or aryl);
- CH₂-S-CH₂-phenyl

10 The preferred protecting group has the formula -CH₂-NHCOR wherein R is a lower alkyl having 1 and 8 carbon atoms, phenyl or phenyl-substituted with lower alkyl, hydroxyl, lower alkoxy, carboxy, or lower alkoxy carbonyl.

15 Labeling with Tc-99m is an advantage of the present invention because the nuclear and radioactive properties of this isotope make it an ideal scintigraphic imaging agent. This isotope has a single photon energy of 140 keV and a radioactive half-life of about 6 hours, and is readily available from a ⁹⁹Mo-^{99m}Tc generator. Other radionuclides known in the prior art have effective half-lives which are much longer (*for example*, ¹¹¹In, which has a half-life of 67.4 h) or are toxic (*for example*, ¹²⁵I).

20 Each specific-binding peptide-containing embodiment of the invention is comprised of a sequence of amino acids. Particular amino acids comprising the peptides of this invention may be L- or D- amino acids, naturally occurring and otherwise; D-amino acids are indicated by a subscript D. Reagents provided by the invention include but are not limited to the following compounds:

Leukocyte Binding Peptides

	<i>formyl</i> .MLFC _{Acm} GC _{Acm}	<i>acetyl</i> .C _{Acm} GC _{Acm} .Aca.(VPGVG) ₄ amide
5	C _{Acm} GC _{Acm} (VGVAPG) ₃	(<i>acetyl</i> .CC _{Acm} GC _{Acm} PLYKKIKKLLLES) ₂ .BSME
	<i>formyl</i> .MLFC _{Acm} GC _{Acm}	<i>acetyl</i> .CGGGPLYKKIKKLLLES
10	C _{Acm} GC _{Acm} TKPR	Pic.GC(VGVAPG) ₃ amide
	<i>formyl</i> .MLFC _{Acm} G.Pica	pGlu.GVNDNEEGFFSARGGCamide
	<i>formyl</i> .Nle.LF.Nle.YKCA _{Acm} GC _{Acm}	<i>acetyl</i> .(LKKL) ₃ C _{Acm} GC _{Acm} amide
15	Pic.GC _{Acm} (VGVAPG) ₃ amide	[BAT].GGPLYKKIKKLLLES
	Pic.GC _{Acm} (VPGVG) ₄ amide	<i>formyl</i> .MLFK.[BAT].amide
	Pic.GC _{Acm} PLYKKIKKLLLES	<i>formyl</i> .Thp.LF.[BAM]
20	C _{Acm} GC _{Acm} GGPLYKKIKKLLLES	<i>formyl</i> .MLFK.[BAT]
	pGlu.GVNDNEEGFFSARC _{Acm} GC _{Acm} amide	[BAT].(VPGVG) ₄ amide
25	(VPGVG) ₄ GGGC _{Acm} GC _{Acm} amide	<i>formyl</i> .MLFK.[BAT].KKKKKamide
	(VGVAPG) ₃ GGGC _{Acm} GC _{Acm} amide	<i>formyl</i> .MLFK.[BAT].GSGSamide
30	<i>acetyl</i> .C _{Acm} GC _{Acm} GGG(VPGVG) ₄ amide	<i>formyl</i> .MLFK.[BAT].E

Leukocyte Binding Peptides (cont'd.)

formyl.MLFK.[BAT].EGE

formyl.MLF(NHCH₂CH₂OCH₂CH₂CH₂CH₂NH)Pic.GC_{Mob}

5 *formyl*.M.DpgF.[BAM]

(*acetyl*.CKKC_{Acm}.GC_{Acm}.PLYKKIKKLLS)₂.BSME

[BAT].(VGVAPG)₃amide

[BAT].GHRPLDKKREEAPSLRPAPPPISGGGYRamide

[DTPA].C_{Acm}.GC_{Acm}.PLYKKIKKLLS

acetyl.KKKKKC_{Acm}.GC_{Acm}.GGPLYKKIKKLLS

10

[BAT].KKLLKKLYKKIKKLLS

(*formyl*.MLFK.[BAT].GGC_{Acm}.GC_{Acm}.GGC.amide)₂.BSME

acetyl.CKKC_{Acm}.GC_{Acm}.PLYKKIKKLLS

Pic.GC_{Acm}.GHRPLDKKREEAPSLRPAPPPISGGGYRamide

15

(*acetyl*.CGC_{Acm}.GC_{Acm}.GGPLYKKIKKLLS)₂.BSME

(*formyl*.MLFKGGC_{Acm}.GC_{Acm}.GGCamide)₂.BSME

[Single-letter abbreviations for amino acids can be found in G. Zubay, *Biochemistry* (2d. ed.), 1988 (MacMillen Publishing: New York) p.33; Dgp = dipropylglycine; pGlu = *pyro*-glutamic acid; Nle = norleucine; Acm = acetamidomethyl; Mob = 4-Methoxybenzyl; Aca = ϵ -aminocaproic acid; Pic = picolinic acid; Pica = picolylamine (2-(aminomethyl)pyridine); [BAT] = *N*⁶,*N*⁹-*bis*(2-methyl-2-mercaptopropyl)-6,9-diazanonoic acid; Thp = 4-aminotetrahydrothiopyran-4-carboxylic acid; [BAM] = *N*⁶,*N*⁹-*bis*(2-methyl-2-mercaptopropyl)-1,6,9-triazanonoic acid; BSME = *bis*-succinimidylmethylether; DTPA = diethylenetriamine pentaacetic acid; peptides are linked to BSME linkers *via* the free thiol moiety of the unprotected cysteine residue (C) in each such peptide).

20

Peptides of the present invention can be chemically synthesized *in vitro*. Peptides of the present invention can generally advantageously be prepared on an amino acid synthesizer. The peptides of this invention can be synthesized wherein the complexing group is covalently linked to the peptide during chemical *in vitro* synthesis, using techniques well known to those with skill in the art. Such peptides covalently-linked to the complexing group upon synthesis are advantageous because specific sites of covalent linkage can be determined therein.

Radiolabel binding moieties of the invention may be introduced into the target specific peptide during peptide synthesis. For embodiments comprising picolinic acid [(Pic-); *e.g.*, Pic-Gly-Cys(protecting group)-], the radiolabel-binding moiety can be synthesized as the last (*i.e.*, amino-terminal) residue in the synthesis. In addition, the picolinic acid-containing radiolabel-binding moiety may be covalently linked to the ϵ -amino group of lysine to give, for example, α N(Fmoc)-Lys- ϵ N[Pic-Gly-Cys(protecting group)], which may be incorporated at any position in the peptide chain. This sequence is particularly advantageous as it affords an easy mode of incorporation into the target binding peptide.

Similarly, the picolylamine (Pica)-containing radiolabel-binding moiety [-Cys(protecting group)-Gly-Pica] can be prepared during peptide synthesis by including the sequence [-Cys(protecting group)-Gly-] at the carboxyl terminus of the peptide chain. Following cleavage of the peptide from the resin the carboxyl terminus of the peptide is activated and coupled to picolylamine. This synthetic route requires that reactive side-chain functionalities remain masked (protected) and do not react during the conjugation of the picolylamine.

Examples of small synthetic peptides containing the Pic-Gly-Cys- and -Cys-Gly-Pica chelators are provided in the Examples hereinbelow. This invention provides for the incorporation of these chelators into virtually any peptide capable of specifically binding to leukocytes *in vivo*, resulting in a radiolabeled peptide having Tc-99m held as neutral complex.

This invention also provides specific-binding small synthetic peptides

which incorporate bisamine bisthiol (BAT or BAM) chelators which may be labeled with Tc-99m. This invention provides for the incorporation of these chelators into virtually any peptide capable of specifically binding to leukocytes *in vivo*, resulting in a radiolabeled peptide having Tc-99m held as neutral complex. An examples of a small synthetic peptide containing a BAT chelator
5 as radiolabel-binding moiety is provided in the Examples hereinbelow.

The specific binding peptides of the invention may also be covalently linked to a polyvalent linking moiety. Polyvalent linking moieties provided by the invention are comprised of at least 2 linker functional groups capable of
10 covalently bonding to platelet-specific moieties, including linear and cyclic peptides. Such functional groups include but are not limited to primary and secondary amines, hydroxyl groups, carboxylic acid groups and thiol reactive groups. Polyvalent linking moieties are comprised of preferably at least three functional groups capable of being covalently linked to platelet-specific moieties,
15 including linear and cyclic peptides. Preferred polyvalent linking moieties include amino acids such as lysine, homolysine, ornithine, aspartic acid and glutamic acid; linear and cyclic amines and polyamines; polycarboxylic acids; activated thiols; and thiol-reactive reagents such as di- and tri-maleimides. Also preferred are embodiments wherein the polyvalent linking moieties
20 comprise a multiplicity of polyvalent linking moieties covalently linked to form a branched polyvalent linking moiety. Most preferred polyvalent linking moieties include *bis*-succinimidylmethylether, *tris*(succinimidylethyl)amine, 4-(2,2-dimethylacetyl)benzoic acid (DMAB) and derivatives thereof.

In forming a complex of radioactive technetium with the reagents of this
25 invention, the technetium complex, preferably a salt of Tc-99m pertechnetate, is reacted with the reagent in the presence of a reducing agent. Preferred reducing agents are dithionite, stannous and ferrous ions; the most preferred reducing agent is stannous chloride. Means for preparing such complexes are conveniently provided in a kit form comprising a sealed vial containing a
30 predetermined quantity of a reagent of the invention to be labeled and a sufficient amount of reducing agent to label the reagent with Tc-99m.

Alternatively, the complex may be formed by reacting a reagent of this invention with a pre-formed labile complex of technetium and another compound known as a transfer ligand. This process is known as ligand exchange and is well known to those skilled in the art. The labile complex
5 may be formed using such transfer ligands as tartrate, citrate, gluconate or mannitol, for example. Among the Tc-99m pertechnetate salts useful with the present invention are included the alkali metal salts such as the sodium salt, or ammonium salts or lower alkyl ammonium salts.

The reaction of the peptides of this invention with Tc-pertechnetate or
10 preformed Tc-99m labile complex can be carried out in an aqueous medium at room temperature. When an anionic complex having a charge of [-1] is formed in the aqueous medium in the form of a salt with a suitable cation such as sodium cation, ammonium cation, mono, di- or tri-lower alkyl amine cation, etc. Any conventional salt of the anionic complex with a pharmaceutically
15 acceptable cation can be used in accordance with this invention.

In a preferred embodiment of the invention, a kit for preparing technetium-labeled peptides is provided. The peptides of the invention can be chemically synthesized using methods and means well-known to those with skill in the art and described hereinbelow. Peptides thus prepared are comprised of
20 between 3 and 100 amino acid residues, and are covalently linked to a radioisotope complexing group wherein the complexing group binds a radioisotope. An appropriate amount of the peptide is introduced into a vial containing a reducing agent, such as stannous chloride, in an amount sufficient to label the peptide with Tc-99m. An appropriate amount of a transfer ligand
25 as described (such as tartrate, citrate, gluconate or mannitol, for example) can also be included. Technetium-labeled peptides according to the present invention can be prepared by the addition of an appropriate amount of Tc-99m or Tc-99m complex into the vials and reaction under conditions described in Example 2 hereinbelow.

30 Radioactively labeled peptides provided by the present invention are provided having a suitable amount of radioactivity. In forming the Tc-99m

radioactive anionic complexes, it is generally preferred to form radioactive complexes in solutions containing radioactivity at concentrations of from about 0.01 millicurie (mCi) to 100 mCi per ml.

5 Technetium-labeled peptides provided by the present invention can be used for visualizing sites of inflammation, including abscesses and sites of "occult" infection. The Tc-99m labeled peptides provided by the present invention can also be used for visualizing sites of inflammation caused by tissue ischemia, including such disorders as inflammatory bowel disease and arthritis. In accordance with this invention, the technetium-labeled peptides or
10 anionic complexes either as a complex or as a salt with a pharmaceutically acceptable cation are administered in a single unit injectable dose. Any of the common carriers known to those with skill in the art, such as sterile saline solution or plasma, can be utilized after radiolabeling for preparing the injectable solution to diagnostically image various organs, tumors and the like
15 in accordance with this invention. Generally, the unit dose to be administered has a radioactivity of about 0.01 mCi to about 100 mCi, preferably 1 mCi to 20 mCi. The solution to be injected at unit dosage is from about 0.01 ml to about 10 ml. After intravenous administration, imaging of the organ or tumor *in vivo* can take place in a matter of a few minutes. However, imaging can
20 take place, if desired, in hours or even longer, after injecting into patients. In most instances, a sufficient amount of the administered dose will accumulate in the area to be imaged within about 0.1 of an hour to permit the taking of scintiphotos. Any conventional method of scintigraphic imaging for diagnostic purposes can be utilized in accordance with this invention.

25 The technetium-labeled peptides and complexes provided by the invention may be administered intravenously in any conventional medium for intravenous injection such as an aqueous saline medium, or in blood plasma medium. Such medium may also contain conventional pharmaceutical adjunct materials such as, for example, pharmaceutically acceptable salts to adjust the
30 osmotic pressure, buffers, preservatives and the like. Among the preferred media are normal saline and plasma.

The methods for making and labeling these compounds are more fully illustrated in the following Examples. These Examples illustrate certain aspects of the above-described method and advantageous results. These Examples are shown by way of illustration and not by way of limitation.

5

EXAMPLE 1

Solid Phase Peptide Synthesis

10 Solid phase peptide synthesis (SPPS) was carried out on a 0.25 millimole (mmole) scale using an Applied Biosystems Model 431A Peptide Synthesizer and using 9-fluorenylmethyloxycarbonyl (Fmoc) amino-terminus protection, coupling with dicyclohexylcarbodiimide/hydroxybenzotriazole or 2-
15 (1H-benzo-triazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate/hydroxybenzotriazole (HBTU/HOBT), and using *p*-hydroxymethylphenoxy-methylpolystyrene (HMP) resin for carboxyl-terminus acids or Rink amide resin for carboxyl-terminus amides. Resin-bound products were routinely cleaved using a solution comprised of trifluoroacetic acid, water, thioanisole, ethanedithiol, and triethylsilane, prepared in ratios of 100 : 5 : 5 : 2.5 : 2 for
20 1.5 - 3 h at room temperature. Where appropriate, N- α -formyl groups were introduced either by treating the free N-terminus of a peptide bound to the resin with formic anhydride in dichloromethane at 0°C for 2h or by treating the cleaved, deprotected peptide with acetic anhydride in 98% formic acid. Where appropriate, N- α -acetyl groups were introduced by treating the free N-
25 terminal amino group of the peptide bound to the resin with 20% (v/v) acetic anhydride in NMP for 30 min. Where appropriate the "Pica" group was introduced by conjugating picolylamine to a precursor peptide using diisopropylcarbodiimide and N-hydroxysuccinimide. Where appropriate, N-terminal [BAT] groups were introduced by treating free N-terminal amino
30 groups of the peptide with *N*⁶,*N*⁹-bis(2-methyl-2-triphenylmethylthiopropyl)-*N*⁶-(*t*-butoxycarbonyl)-6,9-diazanonanoic acid *N*-hydroxysuccinimide ester.

Where appropriate, BSME adducts were prepared by reacting single thiol-containing peptides (5 to 50 mg/mL in 50 mM sodium phosphate buffer,

pH 8) with 0.5 molar equivalents of BMME (*bis-maleimidomethylether*) pre-dissolved in acetonitrile at room temperature for approximately 1 to 18 hours. The solution was concentrated and the product was purified by HPLC.

5 Crude peptides were purified by preparative high pressure liquid chromatography (HPLC) using a Waters Delta Pak C18 column and gradient elution using 0.1% trifluoroacetic acid (TFA) in water modified with acetonitrile. Acetonitrile was evaporated from the eluted fractions which were then lyophilized. The identity of each product was confirmed by fast atom bombardment mass spectroscopy (FABMS) or by electrospray mass
10 spectroscopy (ESMS).

EXAMPLE 2

A General Method for Radiolabeling with Tc-99m

0.1 mg of a peptide prepared as in Example 1 was dissolved in 0.1 mL
15 of 0.05M potassium phosphate buffer (pH 7.4). Tc-99m gluceptate was prepared by reconstituting a Glucoscan vial (E.I. DuPont de Nemours, Inc.) with 1.0 mL of Tc-99m sodium pertechnetate containing up to 200 mCi and allowed to stand for 15 minutes at room temperature. 25 μ l of Tc-99m gluceptate was then added to the peptide and the reaction allowed to proceed
20 at room temperature or at 100°C for 15 to 30 min and then filtered through a 0.2 μ m filter.

The Tc-99m labeled peptide purity was determined by HPLC using a Vydak 218TP54 (RP-18, 5 micron, 220 x 4.6 mm) or Waters DeltaPak (RP-18, 5 micron, 150 x 3.9 mm) analytical column and eluted as described in the
25 Footnotes in Table I. Radioactive components were detected by an in-line radiometric detector linked to an integrating recorder. Tc-99m gluceptate and Tc-99m sodium pertechnetate elute between 1 and 4 minutes under these conditions, whereas the Tc-99m labeled peptide eluted after a much greater amount of time.

30 The following Table illustrates successful Tc-99m labeling of peptides prepared according to Example 1 using the method described herein. Particular

applications of the method are as follows:

HPLC methods (indicated by superscript after R_t in the Table below):

5	Method 1:	Brownlee column	100% A to 100% B ₇₀ in 10 min
	Method 2:	Vydak column	100% A to 100% B ₉₀ in 10 min
	Method 3:	Vydak column	100% A to 100% B ₇₀ in 10 min
	Method 4:	Waters column	100% A to 100% B ₉₀ in 10 min
	Method 5:	Waters column	100% A to 100% B ₉₀ in 20 min

10

wherein: solvent A = 0.1% CF₃COOH/H₂O
solvent B₇₀ = 0.1% CF₃COOH/70% CH₃CN/H₂O
solvent B₉₀ = 0.1% CF₃COOH/90% CH₃CN/H₂O
solvent flow rate = 1 mL/min

15

Vydak column = 218TP54 RP-18, 5 μ , 220mm x 4.6mm analytical column
Brownlee column = Spheri-5, RP-18 5 μ , 220 x 4.6mm column
Waters column = DeltaPak RP-18, 5 μ , 150mm x 3.9mm analytical column

Peptide Reagents	FABMS MH ⁺	Radiochemical Yield	HPLC R _f (min)
C _{Mod} GC _{Acm} PLYKKIKKLLLES	2028	97%	Bound
formyl.MLFC _{Acm} GC _{Acm}	843	100%	11.1, 11.9 ¹
C _{Acm} GC _{Acm} (VGVAPG) ₃ amide	1865	100%	17.7 ¹
formyl.MIFLC _{Acm} GC _{Acm}	957	100%	11.4 ¹
C _{Acm} GC _{Acm} TKPR	906.5	100%	16.1 ¹
formyl.MLFC _{Acm} G.Pica	760	100%	10.9, 12.2 ¹
formyl.Nle.LF.Nle.YKC _{Acm} GC _{Acm}	1230	97%	15.6-16.8 ²
Pic.GC _{Acm} (VGVAPG) ₃ amide	1795	92%	12.4 ²
Pic.GC _{Acm} (VPGVG) ₄ amide	1992	100%	12.0 ¹
Pic.GC _{Acm} PLYKKIKKLLLES	1910	81%	12.9, 13.3 ³
C _{Acm} GC _{Acm} GGPLYKKIKKLLLES	2093	96%	12.6 ³
pGlu.GVNDNEEGHFSARC _{Acm} GC _{Acm} amide	1957	95%	16.3, 16.7 ³
PicGC _{Acm} GHRPLDKKREEAPSLRPAPPISGGYR	3377	94%	11.3 ³
(VPGVG) ₄ GGGC _{Acm} GC _{Acm} amide	2231	67%	11.2, 11.5 ³
(VGVAPG) ₃ GGGC _{Acm} GC _{Acm} amide	2035	33%	10.6 ³
Ac.C _{Acm} GC _{Acm} GGG(VPGVG) ₄ amide	2275	97%	9.6, 9.9 ³
Ac.C _{Acm} GC _{Acm} .Aca.(VPGVG) ₄ amide	2216	76%	11.6, 12.3 ³

5

10

15

Peptide Reagents	FAB/MS MH ⁺	Radiochemical Yield	HPLC R _f (min)
Ac.CGGGPLYKKIHKLLLES	1889	83%	14.1-21.8 ²
Pic.GC(VGVAPG) ₃ amide	1724	100%	17.4 ²
pGlu.GVNDNEEGFFSARGGCamide	1768 [*]	94%	16.6, 12.4 ²
Ac.(LKKL) ₃ C _{Acm} amide	2878	63%	17.0-18.0 ²
[BAT]GGPLYKKIHKLLLES	2006	94%	9.5 ⁴
[BAT]GHRPLDKKREAPSLRPAPPISGGGYRamide	3357	93%	10.4, 11.6 ²
formyl.MLFK.[BAT].amide	884	99%	12.6 ²
formyl.Thp.LF.[BAM]	775 ^{**}	99%	13.3, 13.6 ²
Ac.KKKKKC _{Acm} GC _{Acm} GGPLYKKIHKLLLES	2776	98%	10.2, 11.3 ⁴
formyl.MLFK.[BAT]	884	96%	11.9, 13.7 ²
[BAT].(VPGVG) ₄ amide	1974	96%	11.9, 12.8 ⁴
formyl.MLFK.[BAT].KKKKKamide	1524	96%	11.7, 12.2 ⁴
formyl.MLFK.[BAT].GSGSamide	1315	97%	11.9, 12.8 ⁴
formyl.MLFK.[BAT].E	1013	99%	12.3 ⁴
formyl.M.Dpg.F.[BAM]	1354	98%	13.7 ⁴
formyl.MLFK.[BAT].EGE	1200	98%	12.1 ⁴

5

10

15

20

Peptide Reagents	FABMS MH ⁺	Radiochemical Yield	HPLC R _f (min)
(<i>formyl</i>).MLFK.[BAT].GGC _{Ac} GC _{Ac} GGCamide) ₂ BSME	3477	99%	11.9, 12.4 ⁴
(Ac.CC _{Ac} GC _{Ac} PLYKKIHKLLLES) ₂ BSME	4483	98%	11.6 ⁴
[DTPA]C _{Ac} GC _{Ac} PLYKKIHKLLLES	2468	91%	11.4-14.0 ⁴
(Ac.CKKC _{Ac} GC _{Ac} PLYKKIHKLLLES) ₂ BSME			
(Ac.CGC _{Ac} GC _{Ac} GGPLYKKIHKLLLES) ₂ BSME	4825 [*]	99%	16.2 ⁴
(<i>formyl</i>).MLFK.GGC _{Ac} GC _{Ac} GGCamide) ₂ BSME	2839 [*]		
[BAT].(VGVAPG) ₃ amide	1778	98%	11.4 ⁴
Ac.C _{Ac} GC _{Ac} QAPLYKKIHKLLLES	2220	100%	16.6 ⁵
[BAT].KKLLKKLYKKIHKLLLES	2533	99%	Bound ⁴

Ac = acetyl; other abbreviations as in "Leukocyte Binding Peptides" Table above

* ESMS data (M); ** FABMS data (MNa⁺)

EXAMPLE 3

Scintigraphic Imaging and Biodistribution of Tc-99m Labeled Peptides

In order to demonstrate the effectiveness of Tc-99m labeled peptide reagents as provided above, New Zealand white rabbits were inoculated intramuscularly in the left calf with a potent strain of *E. coli*. After 24 h, the animals were sedated by i.m. injection of ketamine and xylazine, and then injected i.v. with Tc-99m labeled peptide ($\leq 150\mu\text{g}$, 2-10 mCi). The animals were positioned supine in the field of view of a gamma camera (LEAP collimator/ photopeaked for Tc-99m) and imaged over the first hour post-injection, and then at approximately 1h intervals over the next three hours post injection. Animals were allowed to recover between image acquisitions and re-anesthetized as needed.

Upon completion of the final imaging, each animal was sacrificed by overdose of phenobarbital i.v. and dissected to obtain samples of blood and of infected and control muscle tissue. The tissue samples were weighed, and along with a standard amount of the injected dose, were counted using a gamma counter, and the percent injected dose (per gram of tissue) remaining in the tissues was determined. Ratios of percent of injected dose per gram of infected *versus* non-infected muscle tissue, and of infected muscle tissue *versus* blood, were calculated for each peptide. These results are presented in the following Table. Scintiphotos of whole body and leg images of a rabbit injected with a Tc-99m labeled reagent of the invention, having the formula



are presented in Figure 1.

	<u>Peptide Reagents</u>	Infected Muscle (%ID/g)	Control Muscle (%ID/g)	Ratio of Infected/ Control	Blood (%ID/g)	Ratio of Infected/ Blood
5	Ac.C _{Acm} GC _{Acm} GGG(VPGVG) ₄ amide	0.0306	0.0077	3.97	0.049	0.63
	Ac.CGGGPLYKKIKKLLLES	0.0235	0.0050	4.70	0.032	0.74
	formyl.MLFK.[BAT] amide	0.0215	0.0028	7.68	0.006	3.58
	pGlu.GVNDNHEGFFSARC _{Acm} GC _{Acm} amide	0.0165	0.0029	5.68	0.024	0.68
	formyl.M.Dpg.F.[BAM]	0.0106	0.0007	15.14	0.003	3.53
10	PicGC(VGVAPG) ₃ amide	0.0106	0.0019	5.58	0.015	0.69
	(Ac.CC _{Acm} GC _{Acm} PLYKKIKKLLLES) ₂ BSME	0.0082	0.0011	7.45	0.010	0.84
	C _{Acm} GC _{Acm} (VGVAPG) ₃ amide	0.0067	0.0017	3.94	0.011	1.69
	C _{Acm} GC _{Acm} TKPR	0.0060	0.0025	2.40	0.003	2.07
	Ac.KKKKKC _{Acm} GC _{Acm} GGPLYKKIKKLLLES	0.0061	0.0019	5.60	0.006	0.93
15	formyl.Thp.LF.[BAM]	0.0048	0.0010	4.80	0.006	0.83
	[BAT].(VPGVG) ₄ amide	0.0032	0.0006	5.33	0.002	1.68
	[BAT].GGPLYKKIKKLLLES	0.0021	0.0003	7.00	0.004	0.50

(%ID/g) = percent injected dose per gram tissue; other abbreviations are as in the previous Tables.

It should be understood that the foregoing disclosure emphasizes certain specific embodiments of the invention and that all modifications or alternatives equivalent thereto are within the spirit and scope of the invention as set forth in the appended claims.

What is claimed is:

1. A reagent for preparing a scintigraphic imaging agent for imaging sites of inflammation within a mammalian body, comprising a specific binding peptide that specifically binds to leukocytes, covalently linked to a technetium-99m radiolabel-binding moiety.

2. The reagent of Claim 1 wherein the technetium-99m radiolabel-binding moiety has a formula selected from the group consisting of:

I.



wherein Cp is a protected cysteine and (aa) is an amino acid;

II.



wherein A is H, HOOC, H₂NOC, (peptide)-NHOC, (peptide)-OOC or R⁴;

B is H, SH, -NHR³, -N(R³)-(peptide), or R⁴;

X is H, SH, -NHR³, -N(R³)-(peptide) or R⁴;

Z is H or R⁴;

R¹, R², R³ and R⁴ are independently H or lower straight or branched chain or cyclic alkyl;

n is 0, 1 or 2;

and

where B is -NHR³ or -N(R³)-(peptide), X is SH, and n is 1 or 2;

where X is -NHR³ or -N(R³)-(peptide), B is SH, and n is 1 or 2;

where B is H or R⁴, A is HOOC, H₂NOC, (peptide)-NHOC or (peptide)-OOC, X is SH, and n is 0 or 1;

where A is H or R⁴, then where B is SH, X is -NHR³ or -N(R³)-(peptide) and where X is SH, B is -NHR³ or -N(R³)-(peptide);

where X is H or R⁴, A is HOOC, H₂NOC, (peptide)-NHOC or (peptide)-OOC


and B is SH;

where Z is methyl, X is methyl, A is HOOC, H₂NOC, (peptide)-NHOC or (peptide)-OOC, B is SH and n is 0;


where B is SH and X is SH, n is not 0;

and wherein the thiol moiety is in the reduced form; and

III.




IV.




wherein X = H or a protecting group;
(amino acid) = any amino acid;

V.



wherein each R⁵ is independently H, CH₃ or C₂H₅;
each (pgp)^s is independently a thiol protecting group or H;
m, n and p are independently 2 or 3;
A = linear or cyclic lower alkyl, aryl, heterocyclyl, combinations or substituted derivatives thereof;



5

wherein each R^5 is independently H, lower alkyl having 1 to 6 carbon atoms, phenyl, or phenyl substituted with lower alkyl or lower alkoxy;

m , n and p are independently 1 or 2;

10

A = linear or cyclic lower alkyl, aryl, heterocyclyl, combinations or substituted derivatives thereof;

V = H or -CO-peptide;

R^6 = H or peptide;

15

and wherein when V = H, R^6 = peptide and when R^6 = H, V = -CO-peptide; and wherein the radiolabel-binding moiety forms a complex with a radioisotope and the complex is electrically neutral.

3. The reagent of Claim 1 wherein the specific binding peptide and radiolabel binding moiety are covalently linked through one or more amino acids.

20

4. The reagent of Claim 2 wherein the protected cysteine of the radiolabel-binding moiety having formula I has a protecting group of the formula




25

wherein R is a lower alkyl having 1 to 6 carbon atoms, 2-,3-,4-pyridyl, phenyl, or phenyl substituted with lower alkyl, hydroxy, lower alkoxy, carboxy, or lower alkoxycarbonyl.

5. The reagent of Claim 2 wherein the radiolabel-binding moiety of formula Cp(aa)Cp has the formula:

30



6. A scintigraphic imaging agent comprising the reagent of Claim 1 radiolabeled with technetium-99m.

7. The reagent of Claim 1 wherein the specific binding peptide is platelet factor 4 or a derivative thereof.

8. The reagent of Claim 1 comprising the amino acid sequence *formyl*MLF or *formyl*.Nle.LF.Nle or derivatives thereof.

9. The reagent of Claim 1 wherein the specific binding peptide is derived from elastin.


10. The reagent of Claim 1 wherein the specific binding peptide is tuftsin or derivatives thereof.



11. The reagent of Claim 1 wherein the specific binding peptide is fibrinopeptide B, fibrinogen B β -chain or derivatives thereof.

12. The reagent of Claim 7 wherein the reagent is selected from the group consisting of:

$C_{Mab}GC_{Acm}PLYKKIHKLLS$
 $Pic.GC_{Acm}PLYKKIHKLLS$
 $C_{Acm}GC_{Acm}GGPLYKKIHKLLS$
 $acetyl.CGPGPLYKKIHKLLS$
 $[BAT].GGPLYKKIHKLLS$
 $acetyl.KKKKCC_{Acm}GC_{Acm}GGPLYKKIHKLLS$
 $[DTPA].C_{Acm}GC_{Acm}PLYKKIHKLLS$
 $[BAT].KKLLKKLYKKIHKLLS$
 $Ac.C_{Acm}GC_{Acm}QAPLYKKIHKLLS$


Acetyl-NHCHCO-Cys(Acm)-Gly-Cys(Acm)-Pro-Leu-Tyr-Lys-Lys-Ile-Ile-Lys-Lys-Leu-Leu-Glu-Ser






15 13. The reagent of Claim 8 wherein the reagent is selected from the group consisting of:

20 *formyl*.MLFC_{Acm}GC_{Acm}
 formyl.MIFLC_{Acm}GC_{Acm}
 formyl.MLFC_{Acm}GPic_a
 formyl.Nle.LF.Nle.YKC_{Acm}GC_{Acm}
 formyl.MLFK.[BAT].amide
 formyl.Thp.LF.[BAM]
 formyl.MLFK.[BAT]
 25 *formyl*.MLFK.[BAT].KKKKK.amide
 formyl.MLFK.[BAT].GSGS.amide
 formyl.MLFK.[BAT].E
 formyl.M.Dpg.F.[BAM]
 formyl.MLFK.[BAT].EGE





14. The reagent of Claim 9 wherein the reagent is selected from the group consisting of:

- 15
- $C_{Acm}GC_{Acm}(VGVAPG)_3amide$
- $Pic.GC_{Acm}(VGVAPG)_3amide$
- $Pic.GC_{Acm}(VPGVG)_4amide$
- 20 $(VPGVG)_4GGGC_{Acm}GC_{Acm}amide$
- $(VGVAPG)_3GGGC_{Acm}GC_{Acm}amide$
- $aceryl.C_{Acm}GC_{Acm}GGG(VPGVG)_4amide$
- $aceryl.C_{Acm}GC_{Acm}.Aca.(VPGVG)_4amide$
- $Pic.GC(VGVAPG)_3amide$
- 25 $[BAT].(VGVAPG)_3amide$
- $[BAT].(VPGVG)_4amide$

15. The reagent of Claim 11 wherein the reagent is selected from the group consisting of:

- 30 $pGlu.GVNDNEEGFFSARC_{Acm}GC_{Acm}amide$
- $pGlu.GVNDNEEGFFSARGGC.amide$
- $Pic.GC_{Acm}GHRPLDKKREEAPSLRPAPPPISGGGYR$
- $[BAT].GHRPLDKKREEAPSLRPAPPPISGGGYR.amide$

16. The reagent of Claim 10 wherein the reagent is:

- 35 $C_{Acm}GC_{Acm}TKPR$

17. The reagent of Claim 1 wherein the reagent further comprises a polyvalent linking moiety covalently linked to a multiplicity of specific binding

peptides and also covalently linked to a multiplicity of radiolabel-binding moieties to comprise a multimeric polyvalent scintigraphic imaging agent, wherein the molecular weight of the multimeric polyvalent reagent is less than about 20,000 daltons.

5 18. The multimeric polyvalent scintigraphic imaging agent according to Claim 17 wherein the polyvalent linking moiety is *bis*-succinimidyl-methylether, 4-(2,2-dimethylacetyl)benzoic acid, *tris*(succinimidylethyl)amine or a derivative thereof.

10 19. A complex formed by reacting the reagent of Claim 1 with technetium-99m in the presence of a reducing agent.

20 20. The complex of Claim 19, wherein the reducing agent is selected from the group of a dithionite ion, a stannous ion, or a ferrous ion.

 21. A complex formed by labeling the reagent of Claim 1 with technetium-99m by ligand exchange of a prereduced technetium-99m complex.

15 22. A kit for preparing a radiopharmaceutical preparation, said kit comprising sealed vial containing a predetermined quantity of the reagent of Claim 1 and a sufficient amount of reducing agent to label the reagent with technetium-99m.

20 23. A method for imaging a site of inflammation within a mammalian body comprising administering an effective diagnostic amount of the reagent of Claim 1 that is labeled with technetium-99m and detecting the Tc-99m localized at the site of inflammation.

 24. The process of preparing the reagent according to Claim 1 wherein the reagent is chemically synthesized *in vitro*.

25 25. The process of preparing the reagent according to Claim 24 wherein the specific binding peptide is synthesized by solid phase peptide synthesis.

30 26. The reagent according to Claim 1 wherein the radiolabel binding moiety is covalently linked to the specific binding peptide during *in vitro* chemical synthesis.


 27. The reagent according to Claim 26 wherein the radiolabel binding

moiety is covalently linked to the specific binding peptide during solid phase peptide synthesis.

28. A method for labeling a peptide according to Claim 1 comprising reacting the peptide with Tc-99m in the presence of a reducing agent.

5 29. The method of Claim 28, wherein the reducing agent is selected from the group of a dithionite ion, a stannous ion, or a ferrous ion.

**P322 Bi distribution in the Rabbit
24 H ur *E. coli* Infection Model**



I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl. 5 A61K49/02; A61K43/00						
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; border-bottom: 1px solid black; padding: 5px;">Classification System</td> <td style="border-bottom: 1px solid black; padding: 5px;">Classification Symbols</td> </tr> <tr> <td style="padding: 5px;">Int.Cl. 5</td> <td style="padding: 5px;">A61K</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched⁸</div>			Classification System	Classification Symbols	Int.Cl. 5	A61K
Classification System	Classification Symbols					
Int.Cl. 5	A61K					
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹						
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³				
P,X	WO,A,9 213 572 (DIATECH, INC) 20 August 1992 cited in the application see the whole document ---	1-14, 16, 19-29				
X	WO,A,9 010 463 (NEORX CORPORATION) 20 September 1990 cited in the application see abstract see page 6, line 29 - page 18, line 32 see page 26, line 3 - page 27, line 27 see page 29, line 33 - page 30, line 10; claims 1-17, 29-33, 72-75; examples 1-5 ---	1-3, 6, 8, 19-29				
X	EP,A,0 398 143 (THE GENERAL HOSPITAL CORPORATION) 22 November 1990 see the whole document ---	1, 19-29				
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>						
IV. CERTIFICATION						
Date of the Actual Completion of the International Search <div style="text-align: center; font-size: 1.2em;">22 JULY 1993</div>		Date of Mailing of this International Search Report <div style="text-align: center; font-size: 1.2em;">12.08.93</div>				
International Searching Authority <div style="text-align: center; font-weight: bold;">EUROPEAN PATENT OFFICE</div>		Signature of Authorized Officer <div style="text-align: center; font-weight: bold;">HOFF P.J.</div>				

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category °	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claims No.
X	WO,A,8 910 759 (MALLINCKRODT, INC.) 16 November 1989 see abstract see page 13, line 4 - line 26; claims ---	1,19-29
X	WO,A,9 116 919 (NEW ENGLAND DEACONESS HOSPITAL CORPORATION) 14 November 1991 see abstract see page 25, line 21 - page 27, line 13 see page 32, line 1 - page 33, line 17; claims ---	1,6,9, 19-29
A	see abstract see page 25, line 21 - page 27, line 13 see page 32, line 1 - page 33, line 17; claims ---	14
A	INORGANIC CHEMISTRY vol. 29, no. 16, 1990, pages 2948 - 2951 N. BRYSON ET AL. 'PROTECTING GROUPS IN THE PREPARATION OF THIOLATE COMPLEXES OF TECHNETIUM' cited in the application see the whole document ---	11-16
A	BIOCONJUGATE CHEMISTRY vol. 1, no. 1, 1990, pages 132 - 137 K.E. BAIDOO ET AL. 'SYNTHESIS OF A DIAMINEDITHIOL BIFUNCTIONAL CHELATING AGENT FOR INCORPORATION OF TECHNETIUM-99M INTO BIOMOLECULES' cited in the application see the whole document ---	1-16
A	EP,A,0 403 243 (MERCK FROSST CANADA INC.) 19 December 1990 see abstract see page 4, line 25 - line 35; claims ---	1-16
A	EP,A,0 174 853 (MALLINCKRODT INC.) 19 March 1986 see abstract; claims -----	17-18

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Claims searched completely. 4-5, 12-16.
Claims searched in completely: 1-3, 6-11, 17-29.
see annex!
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

REMARK BOX I.2:

In view of the large number of compounds which are defined by the general formulas of claims 1-2, the search was limited to the general idea of the invention, e.g. for the compounds mentioned in the examples and in the claims 12-16. (PCT: art.6, Guidelines Part B, Chapter II.7 last sentence and Chapter III, 3.7).

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9302320
SA 72718

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

22/07/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9213572	20-08-92	AU-A- 1411792	07-09-92
WO-A-9010463	20-09-90	US-A- 4986979	22-01-91
		EP-A- 0463116	02-01-92
		JP-T- 4504129	23-07-92
EP-A-0398143	22-11-90	AU-A- 5659090	29-11-90
		CA-A- 2016235	09-11-90
		JP-T- 4505761	08-10-92
		WO-A- 9013317	15-11-90
WO-A-8910759	16-11-89	AU-A- 3778989	29-11-89
		EP-A- 0381713	16-08-90
WO-A-9116919	14-11-91	AU-A- 7992891	27-11-91
EP-A-0403243	19-12-90	CA-A- 2019035	16-12-90
		JP-A- 3081295	05-04-91
EP-A-0174853	19-03-86	US-A- 4837003	06-06-89
		AU-B- 595164	29-03-90
		AU-A- 4737685	20-03-86
		CA-A- 1276878	27-11-90
		EP-A- 0350972	17-01-90
		EP-A- 0397213	14-11-90
		JP-A- 61072723	14-04-86

EPO FORM P0179

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82